10-Q: IN8bio Reports Q2 2025, Advances Pipeline Amid Funding Needs

IN8bio, a clinical-stage biopharmaceutical company, reported reduced net losses and operating expenses in Q2 2025, while advancing its gamma-delta T cell product candidates despite ongoing going concern doubts.

Summary

• Reported a net loss of $5.1 million for the three months ended June 30, 2025, a significant reduction from $8.6 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $10.6 million, down from $17.2 million in the prior year period.
• Research and development expenses decreased to $2.5 million for Q2 2025 from $5.2 million in Q2 2024, and to $5.5 million for the six months ended June 30, 2025, from $10.1 million in the prior year period.
• General and administrative expenses decreased to $2.7 million for Q2 2025 from $3.5 million in Q2 2024, and to $5.4 million for the six months ended June 30, 2025, from $7.3 million in the prior year period.
• Cash and restricted cash at the end of Q2 2025 was $13.5 million, up from $11.4 million at the beginning of the period.
• Successfully raised approximately $7.4 million in net proceeds from its ATM program and $2.3 million from warrant exercises during the six months ended June 30, 2025.
• INB-100 Phase 1 trial for AML demonstrated 100% complete remission, progression-free survival, and overall survival rates at one-year post-transplant for AML patients, exceeding historical control groups.
• INB-200 Phase 1 trial for GBM showed a median progression-free survival of 16.1 months for patients receiving repeated doses, more than double the standard-of-care (6.9 months).
• Suspended enrollment in the INB-400 Phase 2 clinical trial for GBM in September 2024 to conserve cash, while seeking additional funding or partnerships for the program.
• Introduced INB-600, a proprietary T cell engager platform, with preclinical data showing targeted cytotoxicity against leukemia cell lines and elimination of disease-causing B cells in lupus samples with minimal inflammatory cytokine release.

Sentiment

Score: 6

Explanation: The filing presents a mixed but cautiously optimistic outlook. While the company has significantly reduced its net loss and operating expenses, and reported very strong clinical data for its lead programs (INB-100 and INB-200), the explicit 'going concern' warning and continued reliance on future capital raises introduce substantial financial risk. The positive clinical advancements and cost-cutting efforts are strong, but the fundamental liquidity challenge remains a significant concern.

Positives

• Reduced net loss by 40.9% for the three months ended June 30, 2025, compared to the same period in 2024, indicating improved financial efficiency.
• Operating expenses significantly decreased by $3.5 million (40.2%) in Q2 2025 compared to Q2 2024, driven by lower personnel and direct clinical costs.
• Cash balance increased to $13.2 million as of June 30, 2025, from $11.1 million at December 31, 2024, supported by financing activities.
• INB-100 Phase 1 trial for AML shows highly promising results with 100% complete remission, progression-free survival, and overall survival at one-year, significantly outperforming control groups.
• INB-200 Phase 1 trial for GBM demonstrates durable remissions, with some patients progression-free for over 4 years and a median PFS of 16.1 months for repeated doses, a 133% increase over standard-of-care.
• Successful capital generation through ATM program ($7.4 million net proceeds) and warrant exercises ($2.3 million) in the first half of 2025.
• Received Orphan Drug Designation for INB-400, which could provide financial incentives and market exclusivity if approved.
• New preclinical data for INB-600 T cell engager platform shows potential for broad therapeutic applications in solid tumors, resistant leukemias/lymphomas, and autoimmune diseases with minimal cytokine release syndrome risk.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern, as existing cash is not anticipated to fund operations for at least 12 months.
• Accumulated deficit reached $132.3 million as of June 30, 2025, reflecting significant historical losses.
• Suspension of patient enrollment in the INB-400 Phase 2 clinical trial due to cash conservation measures, potentially delaying its development.
• Continued reliance on external financing (equity/debt offerings, collaborations) to fund future operations, with no assurance of availability or acceptable terms.
• Workforce reduction of approximately 49% in September 2024, which may lead to loss of institutional knowledge and impact morale.
• The company has not yet generated any product sales and does not expect to in the foreseeable future, maintaining a high-risk profile for investors.

Risks

• Substantial doubt regarding ability to continue as a going concern due to insufficient funding for operations beyond June 2026.
• Raising additional capital may cause significant dilution to stockholders, restrict operations, or require relinquishing rights to product candidates.
• A sale of a substantial number of common stock shares, including from warrant exercises, may cause the stock price to decline.
• Outstanding warrants may not be exercised, and the company may not receive anticipated cash proceeds from their exercise.
• Significant operating losses have been incurred since inception, and substantial losses are anticipated for the foreseeable future, with no guarantee of profitability.
• Ability to raise capital may be limited by SEC rules (baby shelf rules) if public float is less than $75.0 million.
• Limited operating history and no products approved for commercial sale make it difficult to evaluate future viability.
• Dependence on successful clinical development, regulatory approval, and commercialization of gamma-delta T cell product candidates, which is a lengthy, expensive, and uncertain process.
• Interim, 'topline,' and preliminary clinical trial data may change as more patient data become available and are subject to audit and verification.
• Novel approaches to cell therapies present significant challenges in development, manufacturing, and commercialization.
• Clinical and commercial utility of the DeltEx platform is uncertain, and certain aspects of gamma-delta T cell function are poorly understood.
• Difficulties in enrolling and retaining patients in clinical trials could delay or adversely affect clinical development activities.
• Serious adverse events, undesirable side effects, or unexpected properties of product candidates may lead to discontinuation of programs or refusal of regulatory approval.
• Inability to file IND applications or proceed with clinical trials on expected timelines due to regulatory requirements or manufacturing delays.
• Development of combination therapies (e.g., INB-200/400 with chemotherapy) presents increased complexity and challenges.
• Public opinion and scrutiny of cell-based immunotherapy and genetic modification approaches may negatively impact public perception and business operations.
• Significant competition from companies with greater experience and resources, potentially leading to competitors commercializing products more rapidly.
• Complex manufacturing process susceptible to product loss, failure, or variation, which could delay or prevent sufficient supply for trials or commercialization.
• Reliance on single third-party suppliers for critical manufacturing components (automated manufacturing device, lentiviral vectors) poses supply chain risks.
• Reliance on third-party healthcare professionals to administer cells, with risks of incorrect administration or patient injury.
• Inability to develop commercial-scale infrastructure for freezing and thawing gamma-delta T cells without damage or cost-effectively.
• Business involves hazardous materials, requiring compliance with environmental, health, and safety laws, with risks of contamination or injury.
• Reliance on CROs and clinical trial sites, with limited control over their performance and potential for delays or data integrity issues.
• Risk of fraud or other misconduct by employees, principal investigators, consultants, and commercial partners.
• Disruptions at the FDA and other government agencies due to funding shortages or global health concerns could hinder regulatory review and approval.
• Licensing of intellectual property is critical, and breach of license agreements could lead to loss of development and commercialization rights.
• Inability to obtain and maintain broad or robust patent protection could allow competitors to commercialize similar products.
• Legal proceedings alleging intellectual property infringement could be expensive, time-consuming, and negatively impact business success.
• Changes in U.S. or foreign patent law could diminish the value of patents.
• Inability to protect intellectual property rights globally, particularly in countries with weaker IP laws.
• Reliance on third parties requires sharing trade secrets, increasing risk of discovery or misappropriation by competitors.
• Inability to attract and retain highly qualified managerial, scientific, medical, and other personnel, including co-founders William Ho and Dr. Lawrence Lamb.
• Workforce reduction may result in unintended consequences, loss of expertise, and decreased morale.
• Difficulties in managing future organizational growth could disrupt operations.
• Strategic collaborations may not materialize or have intended benefits, or may require relinquishing important rights.
• Information technology systems or data compromises could lead to significant disruptions, regulatory actions, litigation, and reputational harm.
• Ability to use net operating losses to offset future taxable income may be limited by ownership changes (Section 382).
• Exposure to potential product liability suits and other claims, which could result in substantial damages and harm reputation.
• Even if regulatory approvals are obtained, products remain subject to ongoing regulatory oversight and may fail to achieve market acceptance.
• Inability to establish sales and marketing capabilities or secure third-party agreements could hinder commercialization.
• Failure to obtain approval outside the United States would limit market opportunities.
• International operations carry various risks, including different regulatory requirements, reduced IP protection, and economic instability.
• Relationships with healthcare providers and payors are subject to fraud and abuse laws, with potential for substantial penalties for non-compliance.
• Uncertainty of coverage and adequate reimbursement for product candidates could make profitable sales difficult.
• Healthcare legislative reform measures may negatively impact business and results of operations.
• Unstable market and economic conditions, including inflation, interest rate volatility, bank closures, and geopolitical tensions, may adversely affect business and share price.
• Cash deposits exceed federally insured limits, posing a risk of loss if banking institutions fail.
• Lack of research coverage or unfavorable reports from financial analysts could cause stock price and trading volume to decline.
• Increased costs and management time due to operating as a public company and compliance initiatives.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Reverse stock split may reduce market trading liquidity and potentially have an anti-takeover effect.
• Concentration of common stock ownership among existing executive officers, directors, and principal stockholders may prevent new investors from influencing corporate decisions.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts to replace current management.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

The company anticipates incurring additional losses as it advances product candidates through clinical trials and expands its portfolio. Existing cash of $13.2 million as of June 30, 2025, is not expected to fund operations for at least 12 months, indicating a need for substantial additional capital through equity/debt offerings or strategic collaborations. The company expects to complete enrollment of the INB-100 expansion cohort in 2025, with long-term follow-up results anticipated in 2026, and additional preclinical data for INB-600 in the second half of 2025.

Management Comments

• We continue to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility given the ongoing market environment for biotechnology stocks.
• These cash preservation measures may impact our ability and the timing to execute our strategy, including our ability to achieve the anticipated milestones and the timing of data releases and/or regulatory filings for our preclinical and clinical programs.
• To continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of raising additional capital through some combination of equity and/or debt offerings, including through ATM offerings and private placements of securities, and identifying strategic collaborations, licensing or other arrangements to support development of the Company’s product candidates.
• We believe our DeltEx DRI gamma-delta T cell therapeutic approach is demonstrating clinical activity and can be applied to multiple solid tumor types. We are seeking additional funding sources and/or strategic opportunities to potentially partner this program.

Industry Context

The company operates in the highly competitive and rapidly evolving field of immuno-oncology, specifically focusing on gamma-delta T cell therapies and T cell engagers. This is a relatively novel and unproven area of development, presenting both significant opportunities for breakthrough treatments and substantial challenges related to manufacturing complexity, regulatory pathways, and market acceptance. The industry is characterized by extensive R&D, high costs, and a reliance on external funding, with many companies facing similar liquidity challenges and competition for talent and resources.

Comparison to Industry Standards

• INB-100's 100% progression-free survival (PFS) and 100% overall survival (OS) rates at one-year post-transplant for AML patients significantly exceed real-world matched control groups from the Center for International Blood and Marrow Transplant Research (CIBMTR) national database (67.8% PFS and 74.7% OS at one-year) and Kansas University Cancer Center (KUCC) (57.4% PFS and 66.7% OS at one-year).
• Patients receiving repeated doses of INB-200 demonstrated a median progression-free survival (mPFS) of 16.1 months, a +133% increase over the expected 6.9 months mPFS for the standard-of-care Stupp protocol in newly diagnosed GBM patients. These mPFS results have already surpassed the historical median OS of 14.6 months associated with the SOC Stupp protocol alone.
• The INB-600 T cell engager platform's ability to selectively activate gamma-delta T cells and induce robust expansion/activation with minimal inflammatory cytokine release (IL-6, IL-10, IL-17a) differentiates it from traditional CD3-targeting TCEs, which often cause severe cytokine release syndrome (CRS) and T cell exhaustion.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Face substantial dilution risk from future equity raises and potential loss of investment due to going concern uncertainty. However, positive clinical data could drive future value.
• **Employees:** Experienced a significant workforce reduction (49%) in September 2024, which may impact morale and institutional knowledge. Remaining employees face increased workload and uncertainty.
• **Patients:** Benefit from the advancement of promising clinical programs (INB-100, INB-200) offering potential new treatment options for severe diseases. However, delays in programs like INB-400 could limit access to therapies.
• **Creditors:** Face increased risk due to the company's going concern warning and reliance on future capital raises to meet obligations.
• **Suppliers/Partners:** May face uncertainty regarding long-term contracts and payments due to the company's financial condition, but ongoing clinical trials and R&D activities provide continued business.

Next Steps

• Complete enrollment of the expansion cohort for the INB-100 Phase 1 trial in 2025.
• Anticipate long-term follow-up results for the INB-100 expansion cohort in 2026.
• Provide additional updates on INB-200 median overall survival later in 2025.
• Present additional preclinical data for the INB-600 platform in the second half of 2025.
• Seek additional funding sources and/or strategic opportunities to potentially partner the INB-400 program.
• Continue to deploy cash preservation measures to defer or reduce costs.
• Pursue raising additional capital through equity and/or debt offerings, including ATM offerings and private placements.
• Identify strategic collaborations, licensing, or other arrangements to support development of product candidates.

Key Dates

Recommendation

While IN8bio has demonstrated impressive clinical progress with INB-100 and INB-200, showing strong efficacy signals that outperform standard-of-care, the company explicitly states 'substantial doubt about its ability to continue as a going concern.' This severe liquidity risk, despite recent capital raises and cost-cutting, overshadows the clinical positives. A seasoned investor would recognize the high reward potential from the pipeline but would be extremely cautious given the existential financial threat. Until a clear path to sustainable funding is established, the stock remains a speculative 'hold' for those with high risk tolerance, as the downside risk of operational termination is significant, even with promising science.

Keywords

Biopharmaceutical, Gamma-delta T cell, Oncology, Acute Myeloid Leukemia, Glioblastoma, Cell therapy, Immunotherapy, Clinical-stage, INB-100, INB-200, INB-400, INB-600, SEC filing, 10-Q, Clinical trials, Preclinical development, Financial results, Going concern, Capital raise, Warrants, Reverse stock split